2027년 5월 13일
FDA PDUFA target action date for mezigdomide + carfilzomib + dexamethasone, a NDA from Bristol Myers Squibb. This is the date by which the FDA is due to act on the application; it can be extended or the decision can come earlier.
FDA PDUFA 결정 날짜 캘린더